Cellebrite DI Ltd. (CLBT) stock
CLBTNasdaqServices-Prepackaged SoftwareFiscal year ends December 31
$11.12−0.41 (-3.56%)
Close on Nov 16, 2026Market cap $2.77BP/E 35.9Yield –
Cellebrite DI r&d expenses
Research and development expenses are spending on new products and technology.
For fiscal 2025 it was $113.88M, up 15.7% from the year before. The highest annual figure on record is $113.88M in fiscal 2025.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $113.88M | +15.7% |
| FY2024 | Dec 31, 2024 | $98.42M | +16.6% |
| FY2023 | Dec 31, 2023 | $84.39M | +4.7% |
| FY2022 | Dec 31, 2022 | $80.62M | +23.0% |
| FY2021 | Dec 31, 2021 | $65.54M | +20.5% |
| FY2020 | Dec 31, 2020 | $54.38M | +16.8% |
| FY2019 | Dec 31, 2019 | $46.57M | – |
See a number that looks wrong?